Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D

Award Number: R21DK118643
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/07/2019
PERIOD OF PERFORMANCE END DATE: 07/31/2023

Group Awards By:

View Award Description

Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D - Abstract Type 1 diabetes (T1D), one of the most prevalent incurable diseases of childhood, is associated with serious risk of morbidity and mortality due to the development of micro- and macrovascular complications. Complications can be prevented by treatment that achieves physiological or near physiological levels of glucose. Despite innovations in management over the past three decades, pediatric patients of African ancestry (AA) have persistently higher HbA1c than patients of white, European ancestry (EA). Higher HbA1c in AA patients is associated with both higher acute and chronic morbidity and mortality compared to EA patients. Thus, racial disparity in glycemic outcome and the development of complications is a major unresolved failure of current clinical pediatric diabetes treatment. Multiple factors contribute to high-risk levels of mean blood glucose (MBG) in pediatric AA patients compared to EA. AA patients have less access to insulin pumps, perform glucose testing less often, have less contact with diabetes management staff, and may have difficulty relating to management staff due to cultural and socioeconomic differences. Greater occurrence of hypoglycemia is another obstacle to achieving optimal glucose control. These considerations have led us to hypothesize that an intervention targeting this group of major management obstacles will sustainably reduce MBG to levels comparable to EA patients without increased hypoglycemia. In order to test this hypothesis, we will first (Aim 1) conduct focus groups with high- risk AA patients and their families to pre-test our intervention approach and receive feedback from them about how best to implement the program, allowing us to more specifically tailor the intervention to address their perceived barriers. This information will help guide the design of a new tailored intervention (Aim 2) for these patients. In Aim 2, we will demonstrate the feasibility and preliminary efficacy of safely reducing high-risk, complication-producing levels of MBG among AA patients with T1D in a randomized pilot study using innovative hybrid closed-loop pump technology combined with a customized culturally sensitive program of enhanced patient support. This approach will intervene simultaneously with multiple obstacles previously known and currently identified by participants that confront high-risk patients and interfere with optimal management. We have the benefit of an experienced and interdisciplinary investigative team with a track record of research productivity in this area. We have a large, well-characterized, diabetes clinic population. Our patients and families have enthusiastically participated in many clinical research projects in the past. We expect that the experience and insights gained from this project will inform the design and implementation of a subsequent larger effectiveness study to improve outcomes for high-risk pediatric patients with T1D. Frequently Used Abbreviations: AA=African ancestry, EA= European ancestry, HbA1c=Hemoglobin A1c, MBG=mean blood glucose, T1D=Type 1 diabetes, HCL=Hybrid closed-loop, CGM=continuous glucose monitoring


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$130,758 )
2024	2020	CHILDRENS HOSPITAL	200 HENRY CLAY AVE	NEW ORLEANS	LA	70118	ORLEANS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	2/21/2024	NON-COMPETING CONTINUATION	-$130,758
														Subtotal = -$130,758

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	CHILDREN'S HOSPITAL	200 HENRY CLAY AVE	NEW ORLEANS	LA	70118	ORLEANS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	8/10/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $157,330 )
2020	2020	CHILDREN'S HOSPITAL	200 HENRY CLAY AVE	NEW ORLEANS	LA	70118	ORLEANS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	2	7/28/2020	NON-COMPETING CONTINUATION	$157,330
2020	2019	CHILDREN'S HOSPITAL	200 HENRY CLAY AVE	NEW ORLEANS	LA	70118	ORLEANS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	12/19/2019	NEW	$0
														Subtotal = $157,330

Issue Date FY: 2019 ( Subtotal = $276,038 )
2019	2019	CHILDREN'S HOSPITAL	200 HENRY CLAY AVE	NEW ORLEANS	LA	70118	ORLEANS	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	8/6/2019	NEW	$276,038
														Subtotal = $276,038

Grand Total All Awards = $302,610

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D

Award Number: R21DK118643

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/07/2019

PERIOD OF PERFORMANCE END DATE: 07/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer